Summary of evidence to reduce the two-dose infant priming schedule to a single dose of the 13-valent pneumococcal conjugate vaccine in the national immunisation programme in the UK

Shamez Ladhani; Nicholas Andrews; Mary E. Ramsay

doi:10.1016/S1473-3099(20)30492-8

Summary of evidence to reduce the two-dose infant priming schedule to a single dose of the 13-valent pneumococcal conjugate vaccine in the national immunisation programme in the UK

Shamez Ladhani^*, Nicholas Andrews, Mary E. Ramsay

^*Corresponding author for this work

Research output: Contribution to journal › Review article › peer-review

17 Citations (Scopus)

Abstract

Pneumococcal conjugate vaccines (PCVs) are highly effective in preventing invasive and non-invasive pneumococcal infections in all age groups through a combination of direct and indirect protection. In many industrialised countries with established PCV programmes, the maximum benefit of the PCV programme has already been achieved, with most cases now due to non-PCV serotypes. On Jan 1, 2020, the UK changed its childhood pneumococcal immunisation programme from a two-dose infant priming schedule with the 13-valent PCV at 8 and 16 weeks after birth, to a single priming dose at 12 weeks after birth, while retaining the 12-month booster. This decision was made after reviewing the evidence from surveillance data, clinical trials, epidemiological analyses, vaccine effectiveness estimates, and modelling studies to support the reduced schedule. In this Review, we summarise the epidemiology of pneumococcal disease in the UK, the evidence supporting the decision to implement a reduced schedule, and the national and global implications of the proposed schedule.

Original language	English
Pages (from-to)	e93-e102
Number of pages	10
Journal	The Lancet Infectious Diseases
Volume	21
Issue number	4
DOIs	https://doi.org/10.1016/S1473-3099(20)30492-8
Publication status	Published - Apr 2021

Bibliographical note

Funding Information:
SNL does contract research on behalf of St George's University of London and Public Health England for vaccine manufacturers (GlaxoSmithKline, Pfizer, and Sanofi Pasteur) but does not receive any personal remuneration. The Immunisation and Countermeasures Division at Public Health England provides vaccine manufacturers with postmarketing surveillance reports on meningococcal, Haemophilus influenzae, and pneumococcal infections, where the companies are required to submit to the UK Licensing Authority in compliance with their Risk Management Strategy. A cost recovery charge is made for these reports. MER reports grants from GSK, Pfizer, Vaccine Manufacturers, outside the submitted work. NA declares no competing interests.

Publisher Copyright:
© 2021 Elsevier Ltd

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/S1473-3099(20)30492-8

Cite this

@article{abbc791370ae4b92bb6a30bd09e87a58,

title = "Summary of evidence to reduce the two-dose infant priming schedule to a single dose of the 13-valent pneumococcal conjugate vaccine in the national immunisation programme in the UK",

abstract = "Pneumococcal conjugate vaccines (PCVs) are highly effective in preventing invasive and non-invasive pneumococcal infections in all age groups through a combination of direct and indirect protection. In many industrialised countries with established PCV programmes, the maximum benefit of the PCV programme has already been achieved, with most cases now due to non-PCV serotypes. On Jan 1, 2020, the UK changed its childhood pneumococcal immunisation programme from a two-dose infant priming schedule with the 13-valent PCV at 8 and 16 weeks after birth, to a single priming dose at 12 weeks after birth, while retaining the 12-month booster. This decision was made after reviewing the evidence from surveillance data, clinical trials, epidemiological analyses, vaccine effectiveness estimates, and modelling studies to support the reduced schedule. In this Review, we summarise the epidemiology of pneumococcal disease in the UK, the evidence supporting the decision to implement a reduced schedule, and the national and global implications of the proposed schedule.",

author = "Shamez Ladhani and Nicholas Andrews and Ramsay, \{Mary E.\}",

note = "Funding Information: SNL does contract research on behalf of St George's University of London and Public Health England for vaccine manufacturers (GlaxoSmithKline, Pfizer, and Sanofi Pasteur) but does not receive any personal remuneration. The Immunisation and Countermeasures Division at Public Health England provides vaccine manufacturers with postmarketing surveillance reports on meningococcal, Haemophilus influenzae, and pneumococcal infections, where the companies are required to submit to the UK Licensing Authority in compliance with their Risk Management Strategy. A cost recovery charge is made for these reports. MER reports grants from GSK, Pfizer, Vaccine Manufacturers, outside the submitted work. NA declares no competing interests. Publisher Copyright: {\textcopyright} 2021 Elsevier Ltd",

year = "2021",

month = apr,

doi = "10.1016/S1473-3099(20)30492-8",

language = "English",

volume = "21",

pages = "e93--e102",

journal = "The Lancet Infectious Diseases",

issn = "1473-3099",

publisher = "Elsevier Ltd.",

number = "4",

}

Summary of evidence to reduce the two-dose infant priming schedule to a single dose of the 13-valent pneumococcal conjugate vaccine in the national immunisation programme in the UK. / Ladhani, Shamez ; Andrews, Nicholas ; Ramsay, Mary E.
In: The Lancet Infectious Diseases, Vol. 21, No. 4, 04.2021, p. e93-e102.

Research output: Contribution to journal › Review article › peer-review

TY - JOUR

T1 - Summary of evidence to reduce the two-dose infant priming schedule to a single dose of the 13-valent pneumococcal conjugate vaccine in the national immunisation programme in the UK

AU - Ladhani, Shamez

AU - Andrews, Nicholas

AU - Ramsay, Mary E.

N1 - Funding Information: SNL does contract research on behalf of St George's University of London and Public Health England for vaccine manufacturers (GlaxoSmithKline, Pfizer, and Sanofi Pasteur) but does not receive any personal remuneration. The Immunisation and Countermeasures Division at Public Health England provides vaccine manufacturers with postmarketing surveillance reports on meningococcal, Haemophilus influenzae, and pneumococcal infections, where the companies are required to submit to the UK Licensing Authority in compliance with their Risk Management Strategy. A cost recovery charge is made for these reports. MER reports grants from GSK, Pfizer, Vaccine Manufacturers, outside the submitted work. NA declares no competing interests. Publisher Copyright: © 2021 Elsevier Ltd

PY - 2021/4

Y1 - 2021/4

N2 - Pneumococcal conjugate vaccines (PCVs) are highly effective in preventing invasive and non-invasive pneumococcal infections in all age groups through a combination of direct and indirect protection. In many industrialised countries with established PCV programmes, the maximum benefit of the PCV programme has already been achieved, with most cases now due to non-PCV serotypes. On Jan 1, 2020, the UK changed its childhood pneumococcal immunisation programme from a two-dose infant priming schedule with the 13-valent PCV at 8 and 16 weeks after birth, to a single priming dose at 12 weeks after birth, while retaining the 12-month booster. This decision was made after reviewing the evidence from surveillance data, clinical trials, epidemiological analyses, vaccine effectiveness estimates, and modelling studies to support the reduced schedule. In this Review, we summarise the epidemiology of pneumococcal disease in the UK, the evidence supporting the decision to implement a reduced schedule, and the national and global implications of the proposed schedule.

AB - Pneumococcal conjugate vaccines (PCVs) are highly effective in preventing invasive and non-invasive pneumococcal infections in all age groups through a combination of direct and indirect protection. In many industrialised countries with established PCV programmes, the maximum benefit of the PCV programme has already been achieved, with most cases now due to non-PCV serotypes. On Jan 1, 2020, the UK changed its childhood pneumococcal immunisation programme from a two-dose infant priming schedule with the 13-valent PCV at 8 and 16 weeks after birth, to a single priming dose at 12 weeks after birth, while retaining the 12-month booster. This decision was made after reviewing the evidence from surveillance data, clinical trials, epidemiological analyses, vaccine effectiveness estimates, and modelling studies to support the reduced schedule. In this Review, we summarise the epidemiology of pneumococcal disease in the UK, the evidence supporting the decision to implement a reduced schedule, and the national and global implications of the proposed schedule.

UR - https://www.scopus.com/pages/publications/85099177811

U2 - 10.1016/S1473-3099(20)30492-8

DO - 10.1016/S1473-3099(20)30492-8

M3 - Review article

C2 - 33129426

AN - SCOPUS:85099177811

SN - 1473-3099

VL - 21

SP - e93-e102

JO - The Lancet Infectious Diseases

JF - The Lancet Infectious Diseases

IS - 4

ER -

Summary of evidence to reduce the two-dose infant priming schedule to a single dose of the 13-valent pneumococcal conjugate vaccine in the national immunisation programme in the UK

Abstract

Bibliographical note

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this